{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:30:00Z","timestamp":1755797400898,"version":"3.37.3"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.anai.2024.04.013","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T07:10:39Z","timestamp":1719817839000},"page":"43-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["How we treat type 2 low asthma"],"prefix":"10.1016","volume":"133","author":[{"given":"Drew","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Borish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.anai.2024.04.013_bib0001","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1080\/02770903.2017.1373393","article-title":"Improving the asthma disparity gap with legal advocacy? A qualitative study of patient-identified challenges to improve social and environmental factors that contribute to poorly controlled asthma","volume":"55","author":"Harris","year":"2018","journal-title":"J Asthma"},{"issue":"6","key":"10.1016\/j.anai.2024.04.013_bib0002","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.jaip.2018.12.027","article-title":"Lung lavage granulocyte patterns and clinical phenotypes in children with severe, therapy-resistant asthma","volume":"7","author":"Teague","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2024.04.013_bib0003","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/thx.2009.126722","article-title":"Effects of steroid therapy on inflammatory cell subtypes in asthma","volume":"65","author":"Cowan","year":"2010","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.anai.2024.04.013_bib0004","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jaci.2022.06.015","article-title":"Optimizing asthma management: role of long-acting muscarinic antagonists","volume":"150","author":"Casale","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2024.04.013_bib0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.anai.2024.04.013_bib0006","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.anai.2024.04.013_bib0007","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1183\/09031936.94.07020223","article-title":"Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages","volume":"7","author":"Spatafora","year":"1994","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2024.04.013_bib0008","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.intimp.2011.10.011","article-title":"Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor","volume":"12","author":"Kubo","year":"2012","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"10.1016\/j.anai.2024.04.013_bib0009","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJM198803103181004","article-title":"Methotrexate in the treatment of corticosteroid-dependent asthma. A double-blind crossover study","volume":"318","author":"Mullarkey","year":"1988","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2024.04.013_bib0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-114-5-353","article-title":"Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study","volume":"114","author":"Erzurum","year":"1991","journal-title":"Ann Intern Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624002345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624002345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T21:17:24Z","timestamp":1731964644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624002345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1081120624002345"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.04.013","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How we treat type 2 low asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}